
---
title: Carcinoma Lung & Thymoma
markmap:
  colorFreezeLevel: 6
---

## Lung Carcinoma

### Histology
- Small Cell Lung Carcinoma (SCLC)
  - High grade neuroendocrine
  - Rapid growth, early metastasis
  - **Paraneoplastic Syndromes** (SIADH, ACTH, Lambert-Eaton)
- Non-Small Cell Lung Carcinoma (NSCLC)
  - Adenocarcinoma (**Most common**)
    - Peripheral
    - EGFR, ALK, ROS1, KRAS, BRAF mutations
  - Squamous Cell Carcinoma
    - Central
    - Keratin pearls, intercellular bridges
    - Associated with smoking
    - **Hypercalcemia (PTHrP)**
  - Large Cell Carcinoma
    - Diagnosis of exclusion

### Staging
- **TNM Staging** (Crucial for NSCLC)
  - T: Tumor size/extent
  - N: Nodal involvement (Mediastinal nodes - N2/N3 significant)
  - M: Metastasis (Distant - M1)
- SCLC Staging
  - Limited Stage (confined to one hemithorax, manageable by RT field)
  - Extensive Stage (beyond limited)

### Molecular Markers & Targeted Therapy
- **EGFR** (Exon 19 del, L858R) -> TKIs (Erlotinib, Afatinib, Osimertinib)
- **ALK** rearrangement -> ALK Inhibitors (Crizotinib, Alectinib)
- **ROS1** rearrangement -> Crizotinib, Entrectinib
- **PD-L1** expression -> Immunotherapy (Pembrolizumab, Nivolumab, Atezolizumab)
- **KRAS** G12C -> Sotorasib, Adagrasib
- **BRAF** V600E -> Dabrafenib + Trametinib

### Clinical Presentation
- Cough, Hemoptysis, Dyspnea, Weight loss
- Chest pain
- **SVC Syndrome** (Venous congestion)
- **Pancoast Tumor** (Superior sulcus tumor)
  - Shoulder pain, Horner's syndrome (Ptosis, Miosis, Anhydrosis), Ulnar nerve symptoms

### Diagnosis
- Imaging (CXR, **CT Chest** with contrast, PET-CT)
- Biopsy (Bronchoscopy, CT-guided FNA/core biopsy, EBUS-TBNA, Mediastinoscopy, Thoracoscopy)

### Treatment
- NSCLC:
  - Early Stage (I-II): Surgery (Lobectomy, Pneumonectomy) + Adjuvant chemo/RT
  - Locally Advanced (III): Chemoradiation, Surgery + Adjuvant therapy, Targeted therapy/Immunotherapy
  - Metastatic (IV): Targeted therapy, Immunotherapy, Chemotherapy
- SCLC:
  - Limited Stage: Concurrent Chemoradiation
  - Extensive Stage: Chemotherapy +/- Immunotherapy

### Screening
- Low-dose CT (LDCT) for high-risk individuals

## Thymoma

### Classification
- **WHO Classification** (Correlation with prognosis/behavior)
  - Type A: Medullary
  - Type AB: Mixed
  - Type B1: Predominantly cortical
  - Type B2: Cortical (**Most common association with Myasthenia Gravis**)
  - Type B3: Epithelial (Thymic Carcinoma - Low grade)
  - Type C: Thymic Carcinoma (High grade)

### Staging
- **Masaoka-Koga Staging** (**Most commonly used**)
  - Stage I: Macroscopically encapsulated, no invasion
  - Stage II: Macroscopic invasion into mediastinal fat (IIA) or pleura/pericardium (IIB)
  - Stage III: Macroscopic invasion into adjacent organs (Lung, SVC, Chest wall)
  - Stage IV: Pleural/pericardial dissemination (IVA) or Lymphatic/Hematogenous metastasis (IVB)

### Clinical Presentation
- Asymptomatic (often incidental finding)
- **Myasthenia Gravis** (**Most common paraneoplastic syndrome**, ~30-50% of thymoma patients)
- Pure Red Cell Aplasia
- Hypogammaglobulinemia (Good Syndrome)

### Diagnosis
- Imaging (**CT Chest** with contrast)
- Biopsy (Core biopsy or Excisional biopsy - often done during surgery)

### Treatment
- **Surgery** (Complete surgical resection is key, especially for Stage I-III)
- Adjuvant Radiotherapy (For Stage II+, incomplete resection)
- Adjuvant Chemotherapy (For Stage III+, Thymic Carcinoma, incomplete resection)

## INICET Buzzwords
- **EGFR mutation**
- **ALK rearrangement**
- **PD-L1 expression**
- **KRAS G12C**
- **Masaoka-Koga Stage**
- **Myasthenia Gravis**
- **B2 Thymoma**
- **SVC Syndrome**
- **Pancoast Tumor**
- **SIADH (SCLC)**
- **Lambert-Eaton Syndrome (SCLC)**
- **Hypercalcemia (Squamous)**
- **TNM Staging**
- **Epithelial Tumors of Thymus**
- **Complete Resection**
- **LDCT Screening**
